Editas Medicine (EDIT) News Today $1.87 +0.22 (+13.33%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$1.88 +0.01 (+0.80%) As of 09:11 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock EDIT Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Editas Medicine, Cassava Sciences among healthcare stocks to join Russell Microcap; MNKD, OCGN to exitMay 28 at 3:00 PM | seekingalpha.comBrokerages Set Editas Medicine, Inc. (NASDAQ:EDIT) Price Target at $5.36May 26 at 1:49 AM | americanbankingnews.com1 Stock Down 97% That Could Double, According to Wall StreetMay 25, 2025 | fool.comEditas Medicine, Inc. (NASDAQ:EDIT) Given Consensus Rating of "Hold" by BrokeragesEditas Medicine, Inc. (NASDAQ:EDIT - Get Free Report) has received an average recommendation of "Hold" from the fourteen ratings firms that are presently covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a sell recommendation, eight have assigned a hold recomMay 25, 2025 | marketbeat.com400,000 Shares in Editas Medicine, Inc. (NASDAQ:EDIT) Bought by Tang Capital Management LLCTang Capital Management LLC bought a new position in Editas Medicine, Inc. (NASDAQ:EDIT - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 400,000 shares of the company's stock, valued at approximately $5May 21, 2025 | marketbeat.comJacobs Levy Equity Management Inc. Boosts Stock Holdings in Editas Medicine, Inc. (NASDAQ:EDIT)Jacobs Levy Equity Management Inc. lifted its stake in shares of Editas Medicine, Inc. (NASDAQ:EDIT - Free Report) by 33.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 708,409 shares of the company's stock after acquMay 19, 2025 | marketbeat.comEditas Medicine reports breakthrough in liver disease treatmentMay 16, 2025 | uk.investing.comEditas Medicine: A Cautionary Tale for InvestorsMay 15, 2025 | fool.comEditas Medicine at BofA Securities 2025: In Vivo Gene Editing FocusMay 15, 2025 | investing.comRobert W. Baird Lowers Editas Medicine (NASDAQ:EDIT) Price Target to $4.00Robert W. Baird cut their target price on Editas Medicine from $8.00 to $4.00 and set an "outperform" rating on the stock in a report on Tuesday.May 15, 2025 | marketbeat.comA new CFO tasked with taking ‘scrappy’ Editas from last year’s layoffs into new gene editing territoryMay 15, 2025 | finance.yahoo.comEditas Medicine, Inc. (NASDAQ:EDIT) Position Raised by Balyasny Asset Management L.P.Balyasny Asset Management L.P. increased its position in shares of Editas Medicine, Inc. (NASDAQ:EDIT - Free Report) by 647.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,3May 15, 2025 | marketbeat.comStifel Financial Corp Decreases Stake in Editas Medicine, Inc. (NASDAQ:EDIT)Stifel Financial Corp lessened its stake in shares of Editas Medicine, Inc. (NASDAQ:EDIT - Free Report) by 46.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 337,158 shares of the company's stock after selling 287,718 sharesMay 15, 2025 | marketbeat.comEditas Medicine to Present Key Preclinical Data on Gene Editing Advancements at ASGCT and TIDES ConferencesMay 14, 2025 | nasdaq.comStylus Medicine launches with $85m to advance in vivo gene editingMay 14, 2025 | msn.comEditas Medicine First Quarter 2025 Earnings: Revenues Beat Expectations, EPS LagsMay 14, 2025 | finance.yahoo.comEditas Medicine, Inc. (EDIT) BofA Securities 2025 Healthcare Conference (Transcript)May 14, 2025 | seekingalpha.comEditas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the European Hematology Association 2025 Congress in JuneMay 14, 2025 | globenewswire.comEditas Medicine Reports New In Vivo Data Highlighting the Potential of Editas' Gene Upregulation Strategy in HSCs at the American Society of Gene and Cell Therapy Annual MeetingMay 14, 2025 | globenewswire.comEditas Medicine Reports New In Vivo Proof of Concept Data in an Undisclosed Liver Target at the American Society of Gene and Cell Therapy Annual MeetingMay 13, 2025 | globenewswire.comEditas Medicine, Inc.: Editas Medicine Announces First Quarter 2025 Results and Business UpdatesMay 13, 2025 | finanznachrichten.deEditas Medicine Announces First Quarter 2025 Results and Business UpdatesMay 12, 2025 | globenewswire.comEditas Medicine Announces U.S. Court of Appeals for the Federal Circuit Remands CRISPR Patent Interference to Patent Trial and Appeal BoardMay 12, 2025 | globenewswire.comRaymond James Financial Inc. Makes New $303,000 Investment in Editas Medicine, Inc. (NASDAQ:EDIT)Raymond James Financial Inc. bought a new stake in shares of Editas Medicine, Inc. (NASDAQ:EDIT - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 238,967 shares of the company's stock, vMay 12, 2025 | marketbeat.comWells Fargo & Company MN Sells 318,436 Shares of Editas Medicine, Inc. (NASDAQ:EDIT)Wells Fargo & Company MN trimmed its holdings in shares of Editas Medicine, Inc. (NASDAQ:EDIT - Free Report) by 63.1% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 186,329 shares of the company's stockMay 10, 2025 | marketbeat.comEditas Medicine (EDIT) to Release Quarterly Earnings on WednesdayEditas Medicine (NASDAQ:EDIT) will be releasing its Q1 2025 earnings before the market opens on Wednesday, May 14. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-14-editas-medicine-inc-stock/)May 9, 2025 | marketbeat.comSusquehanna Fundamental Investments LLC Takes $346,000 Position in Editas Medicine, Inc. (NASDAQ:EDIT)Susquehanna Fundamental Investments LLC purchased a new position in Editas Medicine, Inc. (NASDAQ:EDIT - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 272,430 shares of the company'sMay 6, 2025 | marketbeat.comEditas Medicine to Announce First Quarter 2025 Financial Results and to Participate in Investor Conference in MayMay 5, 2025 | globenewswire.comZacks Research Raises Earnings Estimates for Editas MedicineEditas Medicine, Inc. (NASDAQ:EDIT - Free Report) - Stock analysts at Zacks Research increased their FY2027 EPS estimates for Editas Medicine in a research report issued to clients and investors on Tuesday, April 29th. Zacks Research analyst A. Chakraborty now expects that the company will earn (May 4, 2025 | marketbeat.comAnalysts Offer Predictions for Editas Medicine Q1 EarningsEditas Medicine, Inc. (NASDAQ:EDIT - Free Report) - Investment analysts at HC Wainwright issued their Q1 2025 EPS estimates for Editas Medicine in a research note issued to investors on Monday, April 28th. HC Wainwright analyst M. Kapoor expects that the company will post earnings of ($0.55) perMay 3, 2025 | marketbeat.comEditas Medicine (NASDAQ:EDIT) Upgraded by Cantor Fitzgerald to Strong-Buy RatingCantor Fitzgerald upgraded Editas Medicine from a "hold" rating to a "strong-buy" rating in a research note on Tuesday.May 2, 2025 | marketbeat.comHC Wainwright Upgrades Editas Medicine (NASDAQ:EDIT) to Strong-BuyHC Wainwright raised Editas Medicine to a "strong-buy" rating in a report on Monday.May 1, 2025 | marketbeat.comEditas Medicine, Inc. (NASDAQ:EDIT) Receives Average Recommendation of "Hold" from AnalystsEditas Medicine, Inc. (NASDAQ:EDIT - Get Free Report) has earned a consensus rating of "Hold" from the fourteen ratings firms that are covering the stock, MarketBeat reports. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and three have issued a buy ratingApril 30, 2025 | marketbeat.comHC Wainwright & Co. Initiates Coverage of Editas Medicine (EDIT) with Buy RecommendationApril 29, 2025 | msn.comEditas Medicine to Present Preclinical Data Demonstrating Progress in the Development of an in vivo Gene Editing Pipeline at the American Society of Gene and Cell Therapy Annual MeetingApril 28, 2025 | globenewswire.comRenaissance Technologies LLC Acquires Shares of 1,451,049 Editas Medicine, Inc. (NASDAQ:EDIT)Renaissance Technologies LLC bought a new position in Editas Medicine, Inc. (NASDAQ:EDIT - Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 1,451,049 shares of the company's stock, valued at approximately $1,843,000. ReApril 28, 2025 | marketbeat.comEditas Medicine, Inc. (NASDAQ:EDIT) institutional owners may be pleased with recent gains after 71% loss over the past yearApril 23, 2025 | finance.yahoo.comLeerink Partnrs Predicts Editas Medicine Q3 EarningsEditas Medicine, Inc. (NASDAQ:EDIT - Free Report) - Leerink Partnrs issued their Q3 2025 earnings per share estimates for Editas Medicine in a research report issued on Wednesday, April 16th. Leerink Partnrs analyst M. Foroohar expects that the company will post earnings per share of ($0.14) forApril 20, 2025 | marketbeat.comLeerink Partnrs Forecasts Editas Medicine Q1 EarningsEditas Medicine, Inc. (NASDAQ:EDIT - Free Report) - Leerink Partnrs issued their Q1 2025 EPS estimates for shares of Editas Medicine in a research report issued on Wednesday, April 16th. Leerink Partnrs analyst M. Foroohar forecasts that the company will post earnings per share of ($0.46) for theApril 19, 2025 | marketbeat.comCity Therapeutics Expands Executive Team and Board of DirectorsApril 17, 2025 | finance.yahoo.comGC Therapeutics Expands Leadership Team with Industry Veterans Kai-Hsin Chang and Azadeh GolipourApril 15, 2025 | finance.yahoo.com238,967 Shares in Editas Medicine, Inc. (NASDAQ:EDIT) Bought by Raymond James Financial Inc.Raymond James Financial Inc. purchased a new stake in Editas Medicine, Inc. (NASDAQ:EDIT - Free Report) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 238,967 shares of the company's stock, valued at approximately $303,00April 12, 2025 | marketbeat.comBroad, Harvard researchers win Breakthrough Prize, known as 'Oscars of Science'April 6, 2025 | bizjournals.comEditas Medicine: Do The Risks Outweigh The Rewards?April 3, 2025 | seekingalpha.comZacks Research Comments on Editas Medicine FY2027 EarningsEditas Medicine, Inc. (NASDAQ:EDIT - Free Report) - Stock analysts at Zacks Research issued their FY2027 earnings per share estimates for shares of Editas Medicine in a note issued to investors on Wednesday, March 26th. Zacks Research analyst A. Chakraborty expects that the company will post earnMarch 29, 2025 | marketbeat.comEditas Medicine (NASDAQ:EDIT) Share Price Passes Below 50 Day Moving Average - Here's WhyEditas Medicine (NASDAQ:EDIT) Stock Price Passes Below 50-Day Moving Average - Time to Sell?March 26, 2025 | marketbeat.comEditas Medicine appoints new CFO as Lucera steps downMarch 22, 2025 | investing.comEditas Medicine appoints new CFO amid executive reshuffleMarch 22, 2025 | investing.comEditas Medicine CFO Erick Lucera to step down, Amy Parison to succeedMarch 21, 2025 | markets.businessinsider.comDyne Therapeutics Names Editas Medicine's Lucera as CFOMarch 21, 2025 | marketwatch.com Get Editas Medicine News Delivered to You Automatically Sign up to receive the latest news and ratings for EDIT and its competitors with MarketBeat's FREE daily newsletter. Email Address EDIT Media Mentions By Week EDIT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. EDIT News Sentiment▼0.750.87▲Average Medical News Sentiment EDIT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. EDIT Articles This Week▼64▲EDIT Articles Average Week Get Editas Medicine News Delivered to You Automatically Sign up to receive the latest news and ratings for EDIT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Valneva News Today Tyra Biosciences News Today Eton Pharmaceuticals News Today Opthea News Today Relay Therapeutics News Today REGENXBIO News Today Upstream Bio News Today Arvinas News Today Amylyx Pharmaceuticals News Today CEL-SCI News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:EDIT) was last updated on 5/29/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Editas Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Editas Medicine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy EDIT Stock Free EDIT Stock Alerts